338840 — Y Biologics Income Statement
0.000.00%
- KR₩147bn
- KR₩132bn
- KR₩3bn
Annual income statement for Y Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | — | — | IFRS |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 4,847 | 4,151 | 3,479 |
Cost of Revenue | |||
Gross Profit | 2,388 | 1,336 | 2,389 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Unusual Expense / Income | |||
Total Operating Expenses | 22,212 | 22,899 | 24,858 |
Operating Profit | -17,365 | -18,748 | -21,379 |
Gain / Loss on Sale of Assets | |||
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -17,071 | -18,804 | -20,871 |
Provision for Income Taxes | |||
Net Income After Taxes | -17,071 | -18,804 | -20,871 |
Net Income Before Extraordinary Items | |||
Net Income | -17,071 | -18,804 | -20,871 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -17,071 | -18,804 | -20,871 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -1,232 | -1,350 | -796 |
Dividends per Share |